25-Hydroxycholesterol attenuates tumor necrosis factor alpha-induced blood-brain barrier breakdown in vitro.

25-hydroxycholesterol ABCA1 Blood-brain barrier Brain pericytes Inflammation LXR Oxysterols SREBP-2 TNFα Vascular biology

Journal

Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730

Informations de publication

Date de publication:
22 Aug 2024
Historique:
received: 24 05 2024
revised: 05 08 2024
accepted: 20 08 2024
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 24 8 2024
Statut: aheadofprint

Résumé

Intracellular cholesterol metabolism is regulated by the SREBP-2 and LXR signaling pathways. The effects of inflammation on these molecular mechanisms remain poorly studied, especially at the blood-brain barrier (BBB) level. Tumor necrosis factor α (TNFα) is a proinflammatory cytokine associated with BBB dysfunction. Therefore, the aim of our study was to investigate the effects of TNFα on BBB cholesterol metabolism, focusing on its underlying signaling pathways. Using a human in vitro BBB model composed of human brain-like endothelial cells (hBLECs) and brain pericytes (HBPs), we observed that TNFα increases BBB permeability by degrading the tight junction protein CLAUDIN-5 and activating stress signaling pathways in both cell types. TNFα also promotes cholesterol release and decreases cholesterol accumulation and APOE secretion. In hBLECs, the expression of SREBP-2 targets (LDLR and HMGCR) is increased, while ABCA1 expression is decreased. In HBPs, only LDLR and ABCA1 expression is increased. TNFα treatment also induces 25-hydroxycholesterol (25-HC) production, a cholesterol metabolite involved in the immune response and intracellular cholesterol metabolism. 25-HC pretreatment attenuates TNFα-induced BBB leakage and partially alleviates the effects of TNFα on ABCA1, LDLR, and HMGCR expression. Overall, our results suggest that TNFα favors cholesterol efflux via an LXR/ABCA1-independent mechanism at the BBB, while it activates the SREBP-2 pathway. Treatment with 25-HC partially reversed the effect of TNFα on the LXR/SREBP-2 pathways. Our study provides novel perspectives for better understanding cerebrovascular signaling events linked to BBB dysfunction and cholesterol metabolism in neuroinflammatory diseases.

Identifiants

pubmed: 39181516
pii: S0925-4439(24)00473-3
doi: 10.1016/j.bbadis.2024.167479
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

167479

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Rodrigo Azevedo Loiola (RA)

University of Artois, UR2465, Blood-Brain Barrier (BBB) Laboratory, F-62300 Lens, France.

Cindy Nguyen (C)

University of Artois, UR2465, Blood-Brain Barrier (BBB) Laboratory, F-62300 Lens, France.

Shiraz Dib (S)

University of Artois, UR2465, Blood-Brain Barrier (BBB) Laboratory, F-62300 Lens, France.

Julien Saint-Pol (J)

University of Artois, UR2465, Blood-Brain Barrier (BBB) Laboratory, F-62300 Lens, France.

Lucie Dehouck (L)

University of Artois, UR2465, Blood-Brain Barrier (BBB) Laboratory, F-62300 Lens, France.

Emmanuel Sevin (E)

University of Artois, UR2465, Blood-Brain Barrier (BBB) Laboratory, F-62300 Lens, France.

Marie Naudot (M)

Plateforme d'Ingénierie Cellulaire & Analyses des Protéines ICAP, FR CNRS 3085 ICP, Université de Picardie Jules Verne, F-80039 Amiens, France.

Christophe Landry (C)

University of Artois, UR2465, Blood-Brain Barrier (BBB) Laboratory, F-62300 Lens, France.

Jens Pahnke (J)

Translational Neurodegeneration Research and Neuropathology Lab, Department of Clinical Medicine (KlinMed), Medical Faculty, University of Oslo (UiO), Section of Neuropathology Research, Department of Pathology (PAT), Clinics for Laboratory Medicine (KLM), Oslo University Hospital (OUS), Sognsvannsveien 20, NO-0372 Oslo, Norway; Institute of Nutritional Medicine (INUM)/Lübeck Institute of Dermatology (LIED), University of Lübeck (UzL), University Medical Center Schleswig-Holstein (UKSH), Ratzeburger Allee 160, D-23538 Lübeck, Germany; Department of Pharmacology, Faculty of Medicine and Life Sciences, University of Latvia (LU), Jelgavas iela 3, LV-1004 Rīga, Latvia; School of Neurobiology, Biochemistry and Biophysics, The Georg S. Wise Faculty of Life Sciences, Tel Aviv University (TAU), Ramat Aviv, IL-6997801, Israel.

Caroline Pot (C)

Lausanne University Hospital (CHUV), University of Lausanne, Laboratories of Neuroimmunology, Service of Neurology and Neuroscience Research Center, Department of Clinical Neurosciences, CH-1011 Lausanne, Vaud, Switzerland.

Fabien Gosselet (F)

University of Artois, UR2465, Blood-Brain Barrier (BBB) Laboratory, F-62300 Lens, France. Electronic address: fabien.gosselet@univ-artois.fr.

Classifications MeSH